Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
NCT ID: NCT03097848
Last Updated: 2017-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
450 participants
INTERVENTIONAL
2017-05-04
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Treatment of RFA and Sorafenib on Recurrent HCC
NCT01470495
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
NCT02187081
Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma
NCT03988998
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
NCT02129322
Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma
NCT01328223
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sorafenib+RFA group
for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
RFA
for eligible cases, radiofrequency ablation will be given only.
Sorafenib
for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
RFA group
for eligible cases, RFA will be given only.
RFA
for eligible cases, radiofrequency ablation will be given only.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RFA
for eligible cases, radiofrequency ablation will be given only.
Sorafenib
for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Without gender restriction
* With a favorable liver function of Child-Pugh A to B
* No contraindications to RFA and anesthesia
* Diagnosed with Recurrent HCC
* Signed informed consent.
Exclusion Criteria
* Uncontrollable ascites or variceal bleeding
* Impairment in liver function
* Severe disorders in vital organ
* Accompanied with other tumors or infectious disease except hepatitis.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chengdu PLA General Hospital
OTHER
Sichuan Provincial People's Hospital
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
Hunan Cancer Hospital
OTHER
Cancer Hospital of Guangxi Medical University
OTHER
The First People's Hospital of Yunnan
OTHER
Yunnan Cancer Hospital
OTHER
Xiangya Hospital of Central South University
OTHER
Xinqiao Hospital of Chongqing
OTHER
The Second Affiliated Hospital of Chongqing Medical University
OTHER
Henan Cancer Hospital
OTHER_GOV
First Affiliated Hospital of Chongqing Medical University
OTHER
First Affiliated Hospital of Guangxi Medical University
OTHER
Southwest Hospital, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
feng xiaobin
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southwest Hospital
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
kuansheng Ma, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SWHB 019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.